Immix Biopharma (IMMX) Stock Price, News & Analysis

Company Overview

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment. IMX-110 is currently being evaluated in early-phase clinical trials, with initial data assessing safety, tolerability and preliminary signs of clinical benefit. In addition to its flagship program, Immix Biopharma is advancing a pipeline of next-generation myeloid modulators in preclinical development, seeking to expand application across multiple tumor types.

Headquartered in the United States, Immix Biopharma operates research and development facilities dedicated to advancing its immuno-oncology platform through early clinical stages. The management team brings together seasoned professionals in oncology drug development and translational research, supported by collaborations with leading academic and clinical institutions. With a commitment to addressing unmet needs in cancer care, Immix Biopharma is positioned to translate innovative science into potential new therapies for patients worldwide.

Key Stats

• Today's Range: $9.25 to $10.31
• 50-Day Range: $7.87 to $12.02
• 52-Week Range: $1.94 to $12.14
• Volume: 1.60 million shs
• Average Volume: 1.65 million shs
• Market Capitalization: $528.87 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $20.71
• Consensus Rating: Moderate Buy

Immix Biopharma Stock Analysis - MarketRank™

Immix Biopharma scored higher than 59% of companies evaluated by MarketBeat, and ranked 367th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Immix Biopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on no strong buy ratings, 8 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Immix Biopharma has a consensus price target of $20.71, representing about 113.1% upside from its current price of $9.72.

Amount of Analyst Coverage

Immix Biopharma has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Immix Biopharma are expected to grow in the coming year, from ($0.69) to ($0.67) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Immix Biopharma is -11.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Immix Biopharma is -11.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Immix Biopharma has a P/B Ratio of 5.49. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

22.42% of the float of Immix Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Immix Biopharma has a short interest ratio ("days to cover") of 4.63.

Change versus previous month

Short interest in Immix Biopharma has recently increased by 7.86%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Immix Biopharma does not currently pay a dividend.

Dividend Growth

Immix Biopharma does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.03

News Sentiment

Immix Biopharma has a news sentiment score of 0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Immix Biopharma this week, compared to 3 articles on an average week.

Search Interest

4 people have searched for IMMX on MarketBeat in the last 30 days.

MarketBeat Follows

3 people have added Immix Biopharma to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Immix Biopharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

30.30% of the stock of Immix Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

11.26% of the stock of Immix Biopharma is held by institutions.

Company Calendar

• Last Earnings: 8/07/2026
• Today: 8/08/2026
• Next Earnings (Estimated): 8/14/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:IMMX
• CIK: 1873835
• Web: www.immixbio.com
• Phone: 310-651-8041
• Fax: N/A
• Employees: 9
• Year Founded: 2012

Price Target and Rating

• Average Price Target for Immix Biopharma: $20.71
• High Price Target: $27.00
• Low Price Target: $15.00
• Potential Upside/Downside: +113.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.70
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.92)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$29.44 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -73.24%
• Return on Assets: -59.20%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.75
• Quick Ratio: 8.75

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.77 per share
• Price / Book: 5.49

Miscellaneous

• Outstanding Shares: 54,410,000
• Free Float: 37,924,000
• Market Cap: $528.87 million
• Optionable: Optionable
• Beta: 0.11